



amyris

AMYRIS, INC. INVESTOR PRESENTATION

June 2022


FORWARD-LOOKING STATEMENTS

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding 2021 estimated or expected financial results; Amyris' future growth prospects, priorities, and goals; Amyris' expectations regarding its joint venture with ImmunityBio to develop and commercialize a COVID-19 vaccine and the timing thereof; and Amyris' expectations regarding the size and potential growth of its target markets. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris' liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, regulatory approval, production, launch and commercialization of products and brands, risks related to the COVID-19 pandemic and resulting global economic, financial and supply chain disruptions that may negatively impact Amyris' business operations and financial results, risks related to Amyris' reliance on third parties particularly related to supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

NON-GAAP FINANCIAL INFORMATION

To supplement Amyris' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), Amyris uses non-GAAP financial measures that Amyris believes are helpful in understanding our financial results. These non-GAAP financial measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris' historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures, when considered together with financial information prepared in accordance with GAAP, can enhance investors' and analysts' abilities to meaningfully compare our results from period to period, identify operating trends in our business, and track and model our financial performance. In addition, management believes that these non-GAAP financial measures allow for greater transparency into the indicators used by management to understand and evaluate Amyris' business and make operating decisions. Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under GAAP in order to understand Amyris' operating performance. A reconciliation of the non-GAAP financial measures in this presentation to the most directly comparable GAAP financial measure, is provided in the tables attached to this presentation.

Totals in this presentation may not foot due to rounding.



We are making people and our planet healthier as the leading provider of clean, sustainable chemistry

Powered by Amyris


A WINNING BUSINESS MODEL AND ADVANTAGED PORTFOLIO

Biotechnology is capable of remaking most of the world's chemistry. It is better for people and our planet

01

LAB-TO-MARKET

Our proprietary **Lab-to-Market™** operating platform delivers predictable commercialization, unit cost economics and fast time-to-market



02

CONSUMER BRANDS

Our **Consumer Brands** deliver on the No Compromise® promise for health, clean beauty and personal care products that make people and our planet healthier















03

TECHNOLOGY ACCESS

Our **Technology** enables **Access** to unique, sustainable platform molecules to advance the ESG agenda of our partners via collaborations, licenses and ingredients supply



 Better for People & Planet	Lab-to-Market	Consumer ¹	Technology Access ¹
 Beauty, Personal Care & Wellness	✓	BIOSSANCE..  JVN pipette™ ROSE INC	
 Flavor & Fragrance	✓	COSTA BRAZIL	
 Food & Beverage	✓	purecane™	
 Human Health	✓		
 Materials, Chemicals, Energy	✓		

¹ Amyris has 10 consumer brands in its portfolio plus 2 capabilities: MG Empower and Beauty Labs



SCIENCE MAKING PEOPLE AND PLANET HEALTHIER

- Continued mix shift toward Consumer revenue in Clean Beauty and Personal Care. 60% of Core revenue in Q1 2022, up from 19% in Q1 2019
- Accelerated Consumer growth by investing in strategic capabilities, including brands, social selling and AI technology  
- Completed strategic transactions and licenses in Flavor & Fragrance, Food & Beverage and Human Health providing technology access to partners that are sector leaders
- Investing in manufacturing and supply chain capability for both Consumer and Ingredients
- Transformed capital structure enables growth. Diversified institutional shareholding and paid down legacy debt

WE PROGRAM CELLS TO CREATE HIGH PERFORMING SUSTAINABLE INGREDIENTS

Genotype Specification Language

(GSL) is a DNA programming language-based design tool invented at Amyris to accelerate design of molecules



Clean Chemistry Powered by Biology

Natural, sustainably sourced ingredients delivering higher performance



SQUALANE: A VERSATILE PLATFORM INGREDIENT



BOSSANCE..



ROSE INC.



B2B third party

SUPERIOR PERFORMANCE

Skincare

- 28% smoother skin¹
- 51% improved moisturization²

Haircare

- 255% more manageable hair³
- 55% improved dry combing³

CBD absorption

- > 10X better CBD penetration⁴

SCALABILITY & COST REDUCTION

Renewable crop

- Sugarcane is rapidly renewable, always available

Consistent production

- Fermentation provides stable manufacturing

Speed to market

- Fewer process steps equals faster production

SUSTAINABILITY

Less than 0.1% hectare of sugarcane

size of an 8 x 10 rug



One kg of Squalane



3 sharks killed
depending on size of species

1. After 4 weeks. Clinical study performed on 30 women, ages 40-60
2. 1 hour after application. Clinical study performed on 30 women ages 40-60
3. Compared to control formulation
4. Better than Jojoba, Sunflower, CCT, and Hemp Seed Oil. Using 1% CBD EpiSkin -24 hours

HEMISQUALANE MEETS ALL CONSUMER EXPECTATIONS IN HAIR CARE

Silicone-free



Sustainable



Penetrate the hair shaft to nourish hair



Improve combability



Reduce hair frizz



Reduce damage



Prevent breakage



Strengthen hair



Provide thermal protection



Protect hair from color degradation





Investor Presentation | June 2022

amyris

THE PORTFOLIO CONNECTION


OUR NO COMPROMISE
INGREDIENTS POWER OUR

AWARD-WINNING
FAMILY OF CONSUMER BRANDS

amyris © 2022 Amyris, Inc. All Rights Reserved.

MULTI-FACETED CONSUMER BRAND VALUE CREATION

Consumer digital engagement: AI and machine learning



Digitally native brands: Ecommerce, data analytics and insights




Consumer operations: fulfillment and shipping



Product development: formulation and packaging development



Connecting brands with global audiences: creators, influencers, social media



Brand and revenues: brand creation, brand and channel management

*Unique end-to-end capability:
Create the molecule, produce the ingredient at scale, formulate sustainable consumer products, engage the consumer*

**BEAUTY
• LABS •**

**MG
empower.**

**Powered by
Amyris**

BIOSANCE.
ROSE INC.
pipette™
JWN



The Best Clean Beauty Products of 2022

Best Toner: Biossance

Best Clean Conditioner: JVN



The Best Sustainable Beauty Products of 2022

Best Cleanser: Biossance

Best Eye Cream: Rose Inc.



The Glamour Beauty Awards Readers' Choice Winners

Best Face Oil: Biossance



INVESTING IN THE FUTURE

01

SUPPORTING GROWTH

Stripes

MENOLABS

**ECO
FAB
ULOUS**


SEPHORA

Walmart+

- Developing new homegrown consumer brands
- Value enhancing M&A
- Focused on Beauty and Personal Care markets

02

ENABLING INNOVATION AND COMMERCIALIZATION



R&D technology and infrastructure investments

- Further reducing development time, increasing R&D productivity and lowering per-project cost



- Increasing number of molecules under concurrent development

R&D laboratories and pilot plant expansion

- Maintaining our lead in scale up and manufacturing ability

03

OPERATING WITH EXCELLENCE



Brazil Ingredients plant and U.S. Consumer production facility

- Insourcing manufacturing
- Reduced supply chain dependency on third parties
- Increased agility
- Margin enhancing capital investments



Shared Business Services, ERP and system upgrades to ensure scalability to support business growth

BARRA BONITA STRATEGIC FERMENTATION PLANT INVESTMENT TO TAKE CONTROL OF OUR DESTINY



Strategically located next to Raizen, the world's second largest sugar mill of its kind. Ensures continuity of supply and favorable feedstock economics


Our plant has a proprietary design. The process tower is 2-times taller than our old plant to let gravity do its work in a vertical fermentation process

The site is large. 185,000 m² land area; 1,500 process equipment components; 50 KM of process piping; a 4,000-ton steel structure

Investing in scaled precision fermentation expertise and capacity is critical to making a commercial impact through biotechnology. We are taking control of our destiny

2022 FY OUTLOOK

Revenue \$m	2021	YoY%
Consumer	92.0	+150%
Technology Access	96.0	+40%
Core	188.0	
Strategic Transactions	154	--



- Revenue outlook based on current consumer revenue performance, along with the Q3 launch of new brands. Continued traction with large omnichannel distributors and major retailers
- New in-house ingredients capacity from Barra Bonita to take full effect in the second half of the year expected to alleviate ingredients capacity constraints
- 2022 Technology access includes an estimated \$39m earnout (part of a 3-year earnout)

STRONG FOUNDATION FOR CONTINUED GROWTH

CONSUMER FAMILY OF BRANDS

- **New brand launches:** launched five new consumer brands during 2021 for a total of eight. Expected to introduce three new brands in 2022
- **Product line extensions:** adding new and novel formulations to existing brands – deliver No Compromise® newness
- **Channel expansion:** continue to expand consumer outreach in both offline (brick and mortar) and online (ecommerce) channels – be where the consumer is at
- **Geographic expansion:** extending global reach in UK, Europe, Middle East, Asia Pacific and Latin America

TECHNOLOGY ACCESS

- **No Compromise® standard:** lowest cost, best performing and most sustainably sourced
- **Best Efficacy:** proven to be healthier for people and for the planet
- **Effective solutions:** formulation expertise to enable faster adoption into products
- **Enabling ESG agenda:** our Ingredients deliver unique, natural, sustainably sourced, platform molecules that enable the ESG agenda of industry leaders
- **Strategic partnerships:** partnering with sector leaders in respective end-market to drive adoption, sustainability and growth